$HAE Cashflow Statement | Understand Stock

$HAE

$119.97 +$0.78 (0.65%) Close

$HAE Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2026 12 months to Mar 28, 2026	FY2025 12 months to Mar 29, 2025	FY2024 12 months to Mar 30, 2024	FY2023 12 months to Apr 1, 2023	FY2022 12 months to Apr 2, 2022
Cash Flows from Operating Activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
Amortization of fair value inventory step-up
Share-based compensation expense
Gain on divestiture and sale of assets
Gains on divestiture and sale of assets
Contingent consideration
Impairment of intangible assets
Gain on repurchase of convertible senior notes, net
Gains on sales of property, plant and equipment
Remeasurement of contingent consideration
Deferred income taxes
Amortization of deferred financing costs
Provision (benefit) for losses on inventory
Other non-cash operating activities
Change in operating assets and liabilities:
Change in accounts receivable
Change in inventories
Change in prepaid income taxes
Change in other assets and other liabilities
Change in accounts payable and accrued expenses

Net cash provided by operating activities
Cash Flows from Investing Activities:
Capital expenditures
Proceeds from divestiture and sale of assets
Proceeds from sale of property, plant and equipment
Non-cash transfers from inventory to property, plant and equipment for Haemonetics equipment
Tenant improvement allowances excluded from capital expenditures
Acquisitions
Other investments
Net cash used in investing activities

Cash Flows from Financing Activities:
Proceeds from issuance of convertible notes
Repayment and repurchase of convertible notes
Purchase of capped call related to convertible notes
Term loan borrowings
Term loan redemption
Repayment of term loan borrowings
Proceeds from revolving facility
Payments on revolving facility
Debt issuance costs
Net decrease in short-term loans
Contingent consideration payments
Proceeds from employee stock purchase plan
Proceeds from exercise of stock options
Cash used to net share settle employee equity awards
Share repurchases
Other financing activities
Net cash (used in) provided by financing activities

Effect of exchange rates on cash and cash equivalents
Net Change in Cash and Cash Equivalents
Cash and Cash Equivalents at Beginning of Year
Cash and Cash Equivalents at End of Year
Supplemental Disclosures of Cash Flow Information:
Interest paid
Income taxes paid
Fair value of previously held equity interest settled in connection with acquisition
Settlement of pre-existing loan in connection with acquisition

Comments